Dr. Taiel completed her doctorate in Medicine with board certified in Ophthalmology from Lariboisiere Saint Louis University, Paris, France, and her Associate Professor degree. Dr Taiel has been engaged in the Pharma Industry for 25 years. She hold international and management positions in various therapeutic areas at Servier, Pfizer and Eli Lilly. Then, she led the development of antisense oligonucleotides in Inherited Retinal diseases at ProQR Therapeutics. Since 2018, she leads Gene Therapy programs in Inherited Retinal diseases, as the CMO of GenSight Biologics. Dr. Taiel brings extensive years of experience from both academic medicine and pharma industry.